AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18801827
Drug: AVE1625 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVE1625 (20 mg)
Trial: 18556965
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg twice daily for 6 months)
Trial: 16087013
Drug: Single 2.0‐g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2.0‐g dose of azithromycin microsphere formulation
Trial: 16087013
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of levofloxacin, 500 mg/d
Trial: 11577787
Drug: Optimized pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized pharmacotherapy for GAD
Trial: 11577787
Drug: Agent with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agent with demonstrated effectiveness for GAD
Trial: 11577787
Drug: Adequate dosing
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate dosing and duration of treatment
Trial: 11577787
Drug: Adjunctive strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive strategies for refractory patients
Trial: 31972397
Drug: Creative music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creative music therapy (CMT)
Trial: 29574701
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel 12 mg
Trial: 27364955
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg piragliatin twice daily
Trial: 27364955
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg piragliatin twice daily
Trial: 23611405
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Trial: 23611405
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy with docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8
Trial: 23611405
Drug: Concurrent chemotherapy/radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy/radiotherapy (CT/TRT) with docetaxel 20 mg/m² and carboplatin AUC 2 weekly plus 60 Gy TRT
Trial: 23611405
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy and concurrent CT/TRT
Trial: 23611405
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy and concurrent CT/TRT
Trial: 18287590
Drug: Carvedilol (32.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (32.9 +/- 3.5 mg)
Trial: 18287590
Drug: Metoprolol succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol succinate (96.4 +/- 15.9 mg)
Trial: 11105738
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of enteric‐coated fluoxetine weekly
Trial: 11105738
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of enteric‐coated fluoxetine weekly and 20 mg daily fluoxetine
Trial: 9196864
Drug: Iloprost (5-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost (5-day infusion at 2.0 ng/kg per minute for 8 hours per day, followed by a 1-day infusion every 6 weeks)
Trial: 9196864
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg twice daily, oral slow-release formulation)
Trial: 30253405
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice daily for 6 months post-VIU
Trial: 16326163
Drug: Pamphlet based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamphlet based on the FDA Tips for the Savvy Supplement User
Trial: 11289500
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy alone (average TT: 22.2%)
Trial: 11289500
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy with antiplatelet agent (average TT: 20.9%)
Trial: 1458789
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (3.6 g per day)
Trial: 3881108
Drug: Aspirin 990
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 990 mg and dipyridamole 225 mg daily
Trial: 24792139
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (SNAGs and PJM)
Trial: 11125687
Drug: Intra-articular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular ketamine 0.5 mg/kg diluted with saline up to 5 mL
Trial: 11125687
Drug: Intra-muscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-muscular ketamine 0.5 mg/kg
Trial: 11125687
Drug: Saline 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 5 mL intra-articularly (control)
Trial: 3526500
Drug: Leucine treatment
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine treatment
Trial: 28121470
Drug: Wheatgrass (Triticum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheatgrass (Triticum aestivum L.) 3.5 g freeze-dried powder daily for 10 weeks
Trial: 23832863
Drug: 0.3 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 µg/kg SPA (n = 8)
Trial: 23832863
Drug: 0.45 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 µg/kg SPA (n = 8)
Trial: 23832863
Drug: 0.3 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 µg/kg and 0.45 µg/kg SPA
Trial: 19249698
Drug: Modified vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified vaginal hysterectomy method; details on dosage and duration not applicable.
Trial: 19249698
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical methods; details on dosage and duration not applicable.
Trial: 18666468
Drug: L-T4 (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T4 (1.7 ug/kg)
Trial: 16479742
Drug: Polyhexamethylene biguanide
RxNorm normalized name: Polyhexamethylene Biguanide
DrugBank: Polihexanide (DB12277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyhexamethylene biguanide cream
Trial: 10219333
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 mcg/kg subcutaneous injection daily from day 9 until neutrophil count exceeds 0.5 x 10(9)/l for 3 days)
Trial: 10219333
Drug: G-CSF after
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF after second intensification
Trial: 2114414
Drug: Lysine acetyl
RxNorm normalized name: Lysine acetylcysteinate
DrugBank: Nacystelyn (DB17839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine acetyl salicylate (Aspergesic) 1.8 g t.d.s.
Trial: 2114414
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg t.d.s.
Trial: 26088042
Drug: Hydration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration group (increased water intake by 1 to 1.5 l/day)
Trial: 24075206
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with intratracheal bolus administration of surfactant
Trial: 21682970
Drug: Delamanid 100
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid 100 mg daily for 14 days
Trial: 21682970
Drug: Delamanid 200
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid 200 mg daily for 14 days
Trial: 21682970
Drug: Delamanid 300
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid 300 mg daily for 14 days
Trial: 21682970
Drug: Delamanid 400
RxNorm normalized name: delamanid
DrugBank: Delamanid (DB11637)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Delamanid 400 mg daily for 14 days
Trial: 19183825
Drug: Active intervention
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intervention (drug therapy alone or combined with behavioral therapy) for 10 weeks
Trial: 19183825
Drug: Follow-up after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up after stopping therapy for 6 months
Trial: 15572491
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol (200-mcg tablet)
Trial: 9859573
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors (Abciximab, tirofiban, lamifiban, integrelin)
Trial: 8089244
Drug: Chlorhexidine (0.12%)
RxNorm normalized name: chlorhexidine 12 MG
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (0.12%) rinses, 15 ml, 2 times daily for 30 days starting 2 days after extraction
Trial: 8089244
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution rinses for 30 days starting 2 days after extraction
Trial: 28205255
Drug: Maternal antiretroviral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal antiretroviral therapy (ART)
Trial: 19097507
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (n = 32)
Trial: 15998785
Drug: Medium dairy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dairy, increase calcium intake to approximately 1000-1100 mg/d
Trial: 15998785
Drug: High dairy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dairy, increase calcium intake to approximately 1200-1300 mg/d
Trial: 15998785
Drug: Control, continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control, continuous established (<800 mg/d) dietary calcium intake
Trial: 7141392
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 7 to 8 mg/kg/day and 14 to 15 mg/kg/day
Trial: 7141392
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) at 7 to 8 mg/kg/day and 14 to 15 mg/kg/day
Trial: 29064743
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg QD + Metformin 1000 mg BID (COMBO)
Trial: 29064743
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg BID (MET)
Trial: 25495769
Drug: Pulsed ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed ultrasound (PUS) therapy
Trial: 25495769
Drug: Erythromycin phonophoresis
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin phonophoresis (EP) therapy
Trial: 17136563
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate cream once daily for 4 weeks
Trial: 17136563
Drug: Intramuscular alefacept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular alefacept 15 mg for 12 weeks
Trial: 12590402
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mirtazapine and amitriptyline
Trial: 6384455
Drug: Standard WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO oral glucose-electrolyte solution containing 90 mmol of sodium per liter (Group A: 22 infants)
Trial: 6384455
Drug: Oral glucose-electrolyte
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose-electrolyte solution containing 60 mmol of sodium per liter (Group B: 22 infants)
Trial: 6384455
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous therapy (Group C: 21 infants)
Trial: 29059263
Drug: Daily financial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily financial incentives of $60 monthly with $2 deducted for each day of nonadherence to glucose monitoring goals (4 or more checks per day, with 1 or more levels within the goal range of 70-180 mg/dL) during a 3-month intervention period.
Trial: 29059263
Drug: Daily financial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily financial incentives of $60 monthly with $2 deducted for each day of nonadherence to glucose monitoring goals during a 3-month intervention period.
Trial: 19650746
Drug: New inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New inhibitors of the proton pump (potassium-competitive acid blockers)
Trial: 19650746
Drug: Reflux inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflux inhibitors (GABA(B) receptor agonists and mGluR5 antagonists)
Trial: 19650746
Drug: Visceral analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visceral analgesics and growth factors
Trial: 14759379
Drug: Simvastatin plus
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin plus niacin (mean daily dose 13 mg and 2.4 g, respectively)
Trial: 9414969
Drug: Lactose (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (34 g per day)
Trial: 9414969
Drug: Sucrose (34
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (34 g per day)
Trial: 3716756
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg)
Trial: 29791971
Drug: Collagenase Clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase Clostridium histolyticum (CCH) treatment
Trial: 26564457
Drug: Meibomian gland
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meibomian gland tube massage in addition to corticosteroid eye ointment and artificial tears
Trial: 26564457
Drug: Corticosteroid eye
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid eye ointment and artificial tears
Trial: 23700337
Drug: Repeated Exposure
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated Exposure (RE) group; 2 kJ/g; n = 32
Trial: 23700337
Drug: Flavor-Flavor Learning
RxNorm normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavor-Flavor Learning (FFL) group; 2 kJ/g; n = 32
Trial: 23700337
Drug: Flavor-Nutrient Learning
RxNorm normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavor-Nutrient Learning (FNL) group; 6 kJ/g; n = 31
Trial: 10641042
Drug: Enteric-coated peppermint-caraway
RxNorm normalized name: Caraway Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated peppermint-caraway oil combination (90 mg peppermint oil and 50 mg caraway oil)
Trial: 10641042
Drug: Non-enteric-coated peppermint-caraway
RxNorm normalized name: Caraway Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-enteric-coated peppermint-caraway oil combination (90 mg peppermint oil and 50 mg caraway oil)
Trial: 8878595
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 2,000 mg of clarithromycin (CLARI) plus 200 mg of minocycline (MINO), with or without 800 mg of ofloxacin (OFLO)
Trial: 8878595
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 600 mg of rifampin
Trial: 8878595
Drug: Month-long standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Month-long standard regimen of multidrug therapy (MDT) for multibacillary leprosy
Trial: 8878595
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of CLARI-MINO, with or without OFLO
Trial: 1906152
Drug: hMGs following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hMGs following midluteal pre‐treatment with leuprolide
Trial: 6506175
Drug: 39 mg
RxNorm normalized name: fiber 539 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 39 mg elemental iron
Trial: 6506175
Drug: 39 mg
RxNorm normalized name: fiber 539 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 39 mg elemental iron plus 75 mg vitamin C
Trial: 6506175
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vitamin C daily
Trial: 16086912
Drug: 20 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Gy supplemental beam radiation (PSA <10 ng/ml)
Trial: 16086912
Drug: 44 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 Gy supplemental beam radiation (PSA <10 ng/ml)
Trial: 16086912
Drug: 20 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 Gy supplemental beam radiation (PSA >10 ng/ml)
Trial: 16086912
Drug: 44 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 44 Gy supplemental beam radiation (PSA >10 ng/ml)
Trial: 12150649
Drug: Adequate antidepressant
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate antidepressant treatment
Trial: 12150649
Drug: Adequate pharmacotherapy
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate pharmacotherapy
Trial: 282073
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for hypertension
Trial: 25569647
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (Group F)
Trial: 17239279
Drug: Neoadjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant hormonal therapy with bicalutamide
Trial: 17239279
Drug: Escalated-dose external-beam
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated-dose external-beam radiation therapy
Trial: 12481147
Drug: L-arginine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (300 mg/kg)
Trial: 9140680
Drug: Lisinopril 5
RxNorm normalized name: lisinopril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5 mg orally once per day (max 20 mg once per day)
Trial: 9140680
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg orally once per day (max 25 mg twice per day)
Trial: 9140680
Drug: Lisinopril 5-20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5-20 mg once daily
Trial: 9140680
Drug: Captopril 12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5-50 mg daily
Trial: 8197755
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg S(+) ibuprofen daily (3 x 200mg) for 14 days
Trial: 8197755
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg S(+) ibuprofen daily (3 x 300mg) for 14 days
Trial: 3585223
Drug: Dopamine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (1.0 microgram/kg per min) with angiotensin II infusion
Trial: 3585223
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (graded doses: 0.5, 1 and 5 micrograms/kg per min) with angiotensin II (6 ng/kg per min)
Trial: 3585223
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with angiotensin II infusion
Trial: 1646068
Drug: Single-dose dactinomycin
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose dactinomycin (60 micrograms/kg x 1 day)
Trial: 1646068
Drug: Fractionated-dose dactinomycin
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fractionated-dose dactinomycin (15 micrograms/kg/d x 5 days)
Trial: 1274885
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein intake of 29 g
Trial: 1274885
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein intake of 54 g
Trial: 1274885
Drug: Daily protein
RxNorm normalized name: Supra Clens Daily Protein Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily protein intake of 84 g
Trial: 31558274
Drug: 2-implant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-implant group (n=22)
Trial: 31558274
Drug: Single-implant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-implant group (n=11)